

29 April 2013

**Resonance Health Ltd (ASX:RHT) Appendix 4C – 3rd Quarter Cash Flow Report**

Resonance Health Limited today released its third quarter Cash Flow Report for the period ending 31 March 2013.

Cash at 31 March 2013 was \$936,834 representing a decrease of \$94k for the March quarter. This compares to a net cash outflow of \$183k in the previous quarter. The Company continues to have no debt.

Cash receipts in the March 2013 quarter were up 97% on the prior quarter due to an increase in work completed, including image analysis services and project management services for customers utilising FerriScan in multicentre clinical trials. The increase in receipts was also due to prepayments of approximately \$115k for work which has commenced and is due for completed in 2013 and 2014.

Resonance Health provided 1,086 image analysis services in the March quarter, an increase of 7% over the previous quarter and an increase of 18% over the same period in 2012. The Company's major markets performed well with sales volumes increasing in the UK by 32% and in the USA by 29% on the previous quarter. Approximately 85% of the work in the March 2013 quarter related to the use of FerriScan in the non-clinical trial setting demonstrating the increasing use of FerriScan by the international clinical community.

Export Marketing Development Grant funds of \$60k were expected in December 2012 but are now expected in June 2013.

Payments were higher than the previous quarter due partly to the work completed with the FDA for FerriScan<sup>®</sup> and HepaFat-Scan<sup>®</sup>. In January, Resonance Health received clearance from the FDA for FerriScan to be considered a necessary companion diagnostic device for certain patients requiring iron chelation therapy. Additionally, the Company completed its submission of additional information to the FDA on the Company's HepaFat-Scan<sup>®</sup> product for the assessment of fatty liver disease.

For further information please contact:

**Resonance Health**

Liza Dunne  
Managing Director  
T: +61 8 9286 5300  
E: lizad@resonancehealth.com

Naomi Haydari  
Company Secretary  
T: +61 8 9286 5300  
E: naomih@resonancehelath.com

---

+ See chapter 19 for defined terms.

# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Resonance Health Limited

ABN

96 006 762 492

Quarter ended ("current quarter")

31 March 2013

### Consolidated statement of cash flows

<b>Cash flows related to operating activities</b>	Current quarter \$A'000	Year to date \$A'000
1.1 Receipts from customers	489	1,285
1.2 Payments for		
(a) staff costs	(339)	(995)
(b) advertising and marketing	(34)	(126)
(c) research and development	(94)	(182)
(d) leased assets	-	-
(e) other working capital	(119)	(72)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	9	32
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes (paid)/received	-	-
1.7 Other Receipts/Payments		
(a) consulting & professional services	(3)	(74)
(b) statutory & compliance	4	(91)
(c) grants	-	-
<b>Net operating cash flows</b>	<b>(87)</b>	<b>(223)</b>

---

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitment**

		Current quarter	Year to date
		\$A'000	\$A'000
1.8	Net operating cash flows (carried forward)		
<b>Cash flows related to investing activities</b>			
1.9	Payment for acquisition of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	(7)	(20)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (Cash introduced on acquisition of controlled entity)	-	-
	<b>Net investing cash flows</b>	<b>(7)</b>	<b>(20)</b>
<b>1.14</b>	<b>Total operating and investing cash flows</b>	<b>(94)</b>	<b>(243)</b>
<b>Cash flows related to financing activities</b>			
1.15	Proceeds from issues of shares, options, etc.	-	-
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Other (costs of capital raising)	-	-
	<b>Net financing cash flows</b>	<b>-</b>	<b>-</b>
	<b>Net increase (decrease) in cash held</b>	<b>(94)</b>	<b>(243)</b>
1.21	Cash at beginning of quarter/year to date	1,031	1,180
1.22	Exchange rate adjustments to item 1.20	-	-
1.23	<b>Cash at end of quarter</b>	<b>937</b>	<b>937</b>

+ See chapter 19 for defined terms.

**Payments to directors of the entity and associates of the directors**

**Payments to related entities of the entity and associates of the related entities**

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	\$29k
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions	
	\$29K – Directors fees \$0K – Consulting fees	

**Non-cash financing and investing activities**

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A.

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

**Financing facilities available**

*Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).*

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

---

+ See chapter 19 for defined terms.

### Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	337	231
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)		
- Term deposits	600	800
<b>Total: cash at end of quarter</b> (item 1.22)	937	1,031

### Acquisitions and disposals of business entities

	Acquisitions <i>(Item 1.9(a))</i>	Disposals <i>(Item 1.10(a))</i>
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

### Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Naomi Haydari  
Company Secretary

---

+ See chapter 19 for defined terms.